119 related articles for article (PubMed ID: 27543094)
1. Effect of single agent high-dose methotrexate-related acute kidney injury on length of hospitalization and relative dose intensity in adult patients with central nervous system lymphoma.
Steward JS; Bullard HM; O'Rourke TJ; Campbell AD; Brinker BT; Yost KJ; Vanderwoude AC; Scott WL; Kintzel PE
J Oncol Pharm Pract; 2017 Oct; 23(7):496-501. PubMed ID: 27543094
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity.
Wiczer T; Dotson E; Tuten A; Phillips G; Maddocks K
J Oncol Pharm Pract; 2016 Jun; 22(3):430-6. PubMed ID: 26152702
[TBL] [Abstract][Full Text] [Related]
3. Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.
Drost SA; Wentzell JR; Giguère P; McLurg DL; Sabloff M; Kanji S; Nguyen TT
Pharmacotherapy; 2017 Jun; 37(6):684-691. PubMed ID: 28394433
[TBL] [Abstract][Full Text] [Related]
4. A single-center qualitative study evaluating the safety and efficacy of a pharmacist-driven protocol for high-dose methotrexate management.
Matta SF; Gieselman LA; Mancini RS
J Oncol Pharm Pract; 2021 Apr; 27(3):588-595. PubMed ID: 32484382
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
6. Reduced time for urinary alkalinization before high-dose methotrexate with preadmission oral bicarbonate.
Kintzel PE; Campbell AD; Yost KJ; Brinker BT; Arradaza NV; Frobish D; Wehr AM; O'Rourke TJ
J Oncol Pharm Pract; 2012 Jun; 18(2):239-44. PubMed ID: 22075004
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
[TBL] [Abstract][Full Text] [Related]
8. Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?
Ranchon F; Vantard N; Henin E; Bachy E; Sarkozy C; Karlin L; Bouafia-Sauvy F; Gouraud A; Schwiertz V; Bourbon E; Baudouin A; Caffin AG; Vial T; Salles G; Rioufol C
Hematol Oncol; 2018 Apr; 36(2):399-406. PubMed ID: 28983943
[TBL] [Abstract][Full Text] [Related]
9. Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
Ikemura K; Oshima K; Enokiya T; Okamoto A; Oda H; Mizuno T; Ishinaga H; Muraki Y; Iwamoto T; Takeuchi K; Katayama N; Okuda M
Cancer Chemother Pharmacol; 2017 May; 79(5):943-949. PubMed ID: 28364288
[TBL] [Abstract][Full Text] [Related]
10. [Renal toxicity of high-dose methotrexate].
Garcia H; Leblond V; Goldwasser F; Bouscary D; Raffoux E; Boissel N; Broutin S; Joly D
Nephrol Ther; 2018 Apr; 14 Suppl 1():S103-S113. PubMed ID: 29606256
[TBL] [Abstract][Full Text] [Related]
11. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
12. Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia.
Reiss SN; Buie LW; Adel N; Goldman DA; Devlin SM; Douer D
Ann Hematol; 2016 Dec; 95(12):2009-2015. PubMed ID: 27542957
[TBL] [Abstract][Full Text] [Related]
13. High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course.
O'Donoghue DF; Truong HL; Finnes HD; McDonald JS; May HP; Ansell SM; Bennani NN; Habermann TM; Inwards DJ; Johnston PB; Khurana A; Lin Y; Micallef IN; Nowakowski GS; Paludo J; Porrata LF; Thanarajasingam G; Thompson CA; Villasboas JC; Wang Y; Witzig TE; Leung N
JCO Oncol Pract; 2022 Dec; 18(12):e1908-e1917. PubMed ID: 36240468
[TBL] [Abstract][Full Text] [Related]
14. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.
Tsurusawa M; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Koh K; Takimoto T; Saito A; Fujimoto J; Nakazawa A; Horibe K;
Pediatr Blood Cancer; 2015 Feb; 62(2):279-284. PubMed ID: 25359701
[TBL] [Abstract][Full Text] [Related]
15. Successful high-dose methotrexate chemotherapy in a patient with acute lymphocytic leukemia who developed acute renal failure during the initial treatment.
Isoda T; Ito S; Kajiwara M; Nagasawa M
Pediatr Int; 2007 Dec; 49(6):1018-9. PubMed ID: 18045317
[TBL] [Abstract][Full Text] [Related]
16. Lethal side effects of high dose methotrexate therapy.
Taguchi H; Niiya K; Miyoshi I; Machida K; Kuwabara K
Nihon Gan Chiryo Gakkai Shi; 1982 Dec; 17(8):1995-2000. PubMed ID: 7169570
[No Abstract] [Full Text] [Related]
17. Using a Bedside Algorithm to Individually Dose High-dose Methotrexate for Patients at Risk for Toxicity.
Foster JH; Bernhardt MB; Thompson PA; Smith EO; Schafer ES
J Pediatr Hematol Oncol; 2017 Jan; 39(1):72-76. PubMed ID: 27820134
[TBL] [Abstract][Full Text] [Related]
18. Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphoma.
Farhi J; Laribi K; Orvain C; Hamel JF; Mercier M; Sutra Del Galy A; Clavert A; Rousselet MC; Tanguy-Schmidt A; Hunault-Berger M; Moles-Moreau MP
Ann Hematol; 2018 Dec; 97(12):2391-2401. PubMed ID: 30091022
[TBL] [Abstract][Full Text] [Related]
19. High-dose methotrexate for primary CNS lymphoma in the elderly.
Ng S; Rosenthal MA; Ashley D; Cher L
Neuro Oncol; 2000 Jan; 2(1):40-4. PubMed ID: 11302253
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a model to predict acute kidney injury following high-dose methotrexate in patients with lymphoma.
Rice ML; Barreto EF; Rule AD; Martin CE; Truong HL; Mara KC; Kashani KB; Thompson CA; Witzig TE; Barreto JN
Pharmacotherapy; 2024 Jan; 44(1):4-12. PubMed ID: 37926860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
